New hope for lupus patients: experimental drugs show promise in clinical trial
NCT ID NCT03656562
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This study tested two experimental drugs, VAY736 and CFZ533, in 107 people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal was to see if these drugs could reduce disease activity and allow patients to lower their steroid use. The trial was completed and focused on safety, tolerability, and early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, C1015ABO, Argentina
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210008, China
-
Novartis Investigative Site
Shanghai, 200127, China
-
Novartis Investigative Site
Prague, 128 00, Czechia
-
Novartis Investigative Site
Pessac, 33604, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Budapest, 1023, Hungary
-
Novartis Investigative Site
Debrecen, 4032, Hungary
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Nagoya, Aichi-ken, 457 8510, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 460-0001, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 8560, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 162 8655, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 160 8582, Japan
-
Novartis Investigative Site
Bydgoszcz, 85 168, Poland
-
Novartis Investigative Site
Poznan, 60-218, Poland
-
Novartis Investigative Site
Warsaw, 00-874, Poland
-
Novartis Investigative Site
Moscow, 115522, Russia
-
Novartis Investigative Site
Saint Petersburg, 194044, Russia
-
Novartis Investigative Site
Yekaterinburg, 620144, Russia
-
Novartis Investigative Site
Gwangju, 61469, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Taichung, Taiwan ROC, 40201, Taiwan
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Bangkok, 10700, Thailand
Conditions
Explore the condition pages connected to this study.